Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Albumin Max is a multi-ingredient dietary supplement primarily formulated to support liver and kidney function and maintain healthy protein levels in the body. It typically contains a blend of albumin (often derived from egg whites), liver powder, and a comprehensive profile of essential and non-essential amino acids including L-Glutamine, L-Arginine, and branched-chain amino acids (BCAAs) like Leucine, Isoleucine, and Valine. The supplement functions by providing the necessary building blocks for protein synthesis and helping to maintain plasma oncotic pressure, which is crucial for fluid balance. It is often marketed to individuals with protein deficiencies, those recovering from illness, or those seeking to support hepatic health. Unlike intravenous human albumin solutions, Albumin Max is an oral product intended for nutritional support rather than acute volume expansion.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Albumin Max.